Period from 31 March 2023 to
Registration number:
Bodriggy Pharmacy Ltd
Contents
Balance Sheet |
|
Notes to the Unaudited Financial Statements |
Bodriggy Pharmacy Ltd
Balance Sheet
30 November 2023
Note |
30 November |
30 March |
|
Fixed assets |
|||
Tangible assets |
|
|
|
Current assets |
|||
Stocks |
|
|
|
Debtors |
|
|
|
Cash at bank and in hand |
|
|
|
|
|
||
Creditors: Amounts falling due within one year |
( |
( |
|
Net current assets |
|
|
|
Net assets |
|
|
|
Capital and reserves |
|||
Called up share capital |
|
|
|
Other reserves |
|
- |
|
Profit and loss account |
|
|
|
Shareholders' funds |
|
|
Bodriggy Pharmacy Ltd
Balance Sheet
30 November 2023
For the financial period ending 30 November 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
• |
|
• |
The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
These financial statements have been prepared and delivered in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and the option not to file the Profit and Loss Account has been taken.
Approved and authorised by the
......................................... |
Company Registration Number: 08554176
Bodriggy Pharmacy Ltd
Notes to the Unaudited Financial Statements
Period from 31 March 2023 to 30 November 2023
General information |
The company is a private company limited by share capital, incorporated in England & Wales.
The address of its registered office is:
These financial statements were authorised for issue by the
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
Disclosure of long or short period
Revenue recognition
Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts and after eliminating sales within the company.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.
Tax
Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Bodriggy Pharmacy Ltd
Notes to the Unaudited Financial Statements
Period from 31 March 2023 to 30 November 2023
Deferred tax is recognised on all timing differences at the balance sheet date unless indicated below. Timing differences are differences between taxable profits and the results as stated in the profit and loss account and other comprehensive income. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.
The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.
Tangible assets
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Depreciation
Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:
Asset class |
Depreciation method and rate |
Leasehold improvements |
5% straight line |
Fixtures and fittings |
20% straight line |
Computer equipmnent |
50% straight line |
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.
Leases
Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.
Bodriggy Pharmacy Ltd
Notes to the Unaudited Financial Statements
Period from 31 March 2023 to 30 November 2023
Financial instruments
Classification
• Short term trade and other debtors and creditors; and
• Cash and bank balances.
All financial instruments are classified as basic.
Recognition and measurement
Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument and derecognised when in the case of assets, the contractual rights to cash flows from the assets expire or substantially all the risks and rewards of ownership are transferred to another party, or in the case of liabilities, when the company’s obligations are discharged, expire or are cancelled.
Going Concern
The director has considered the going concern status of the company and the wider group that this company is part of. This has included reviewing accounts for the year ended 30 November 2023 together with post year end results and events. While there are financial challenges within the group, the director has continued to prepare the accounts on the going concern basis as he has confidence that action can be taken to mitigate debt and realise cash within the wider group such that the company and group can continue in operational existence for at least 12 months from the date of signing the accounts.
Staff numbers |
The average number of persons employed by the company (including the director) during the period, was
Bodriggy Pharmacy Ltd
Notes to the Unaudited Financial Statements
Period from 31 March 2023 to 30 November 2023
Tangible assets |
Leasehold improvements |
Furniture, fittings and equipment |
Total |
|
Cost or valuation |
|||
At 31 March 2023 |
|
|
|
Additions |
- |
|
|
At 30 November 2023 |
|
|
|
Depreciation |
|||
At 31 March 2023 |
|
|
|
Charge for the period |
|
|
|
At 30 November 2023 |
|
|
|
Carrying amount |
|||
At 30 November 2023 |
|
|
|
At 30 March 2023 |
|
|
|
Stocks |
30 November |
30 March |
|
Other inventories |
|
|
Debtors |
Note |
30 November |
30 March |
|
Trade debtors |
|
|
|
Amounts owed by group undertakings and undertakings in which the company has a participating interest |
|
- |
|
Other debtors |
|
|
|
|
|
Bodriggy Pharmacy Ltd
Notes to the Unaudited Financial Statements
Period from 31 March 2023 to 30 November 2023
Creditors |
Creditors: amounts falling due within one year
30 November |
30 March |
|
Due within one year |
||
Trade creditors |
|
|
Taxation and social security |
- |
|
Accruals and deferred income |
|
|
Other creditors |
|
|
|
|
Share capital |
Allotted, called up and fully paid shares
30 November |
30 March |
|||
No. |
£ |
No. |
£ |
|
Alloted, called & fully paid ordinary shares of £1 each |
1,000 |
1,000 |
1,000 |
1,000 |
Reserves |
The changes to each component of equity resulting from items of other comprehensive income for the current period were as follows:
Other reserves |
Total |
|
Loans from participators forgiven |
|
|
|
Bodriggy Pharmacy Ltd
Notes to the Unaudited Financial Statements
Period from 31 March 2023 to 30 November 2023
Related party transactions |
Transactions with the director |
2023 |
At 31 March 2023 |
Advances to director |
Repayments by director |
At 30 November 2023 |
D K Naidu |
||||
K D Naidu |
- |
|
( |
|
A Sharif |
||||
Asif |
|
- |
( |
- |
T A Amin |
||||
T Amin |
|
- |
( |
- |
2023 |
At 31 March 2022 |
At 30 March 2023 |
A Sharif |
||
Asif |
|
|
T A Amin |
||
T Amin |
- |
|
Parent and ultimate parent undertaking
Bodriggy Pharmacy Limited is a 50% subsidiary of Naimans UK Limited and a 50% subsidiary of Bodriggy Project Ltd. The registered office for the parent company is Reeds Pharmacy, The Globe, Frances Street, Truro, Cornwall, United Kingdom, TR1 3DP. The principal place of business is 60 Queensway, Hayle, Cornwall, TR27 4PB.